EP2285778A4 - Dérivés de nicotinamide - Google Patents

Dérivés de nicotinamide

Info

Publication number
EP2285778A4
EP2285778A4 EP09733745A EP09733745A EP2285778A4 EP 2285778 A4 EP2285778 A4 EP 2285778A4 EP 09733745 A EP09733745 A EP 09733745A EP 09733745 A EP09733745 A EP 09733745A EP 2285778 A4 EP2285778 A4 EP 2285778A4
Authority
EP
European Patent Office
Prior art keywords
nicotinamide derivatives
nicotinamide
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09733745A
Other languages
German (de)
English (en)
Other versions
EP2285778A1 (fr
Inventor
Andrew Katsifis
Ivan Greguric
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CRC for Biomedical Imaging Development Ltd
Original Assignee
CRC for Biomedical Imaging Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2008901989A external-priority patent/AU2008901989A0/en
Application filed by CRC for Biomedical Imaging Development Ltd filed Critical CRC for Biomedical Imaging Development Ltd
Publication of EP2285778A1 publication Critical patent/EP2285778A1/fr
Publication of EP2285778A4 publication Critical patent/EP2285778A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP09733745A 2008-04-22 2009-04-22 Dérivés de nicotinamide Withdrawn EP2285778A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2008901989A AU2008901989A0 (en) 2008-04-22 Nicotinamide derivatives
PCT/AU2009/000504 WO2009129573A1 (fr) 2008-04-22 2009-04-22 Dérivés de nicotinamide

Publications (2)

Publication Number Publication Date
EP2285778A1 EP2285778A1 (fr) 2011-02-23
EP2285778A4 true EP2285778A4 (fr) 2011-05-11

Family

ID=41216339

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09733745A Withdrawn EP2285778A4 (fr) 2008-04-22 2009-04-22 Dérivés de nicotinamide

Country Status (6)

Country Link
EP (1) EP2285778A4 (fr)
CN (1) CN102232067A (fr)
AU (1) AU2009240785A1 (fr)
CA (1) CA2753532A1 (fr)
NZ (1) NZ589360A (fr)
WO (1) WO2009129573A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120107240A1 (en) * 2010-11-03 2012-05-03 The Board Of Trustees Of The Leland Stanford Junior University Probes and methods of melanoma imaging
US20150023877A1 (en) * 2013-07-18 2015-01-22 The Board Of Trustees Of The Leland Stanford Junior University Methods of parkinsons disease diagnosis and monitoring treatment
JP2015193545A (ja) * 2014-03-31 2015-11-05 国立大学法人京都大学 ２−（３−ピリジニル）−１ｈ−ベンズイミダゾール誘導体化合物、これを含む放射性医薬
CN107556236B (zh) * 2017-08-25 2020-01-21 华中科技大学同济医学院附属协和医院 同位素取代的靶向黑色素瘤的正电子显像剂及其制备方法与用途
WO2020004785A1 (fr) * 2018-06-28 2020-01-02 전남대학교 산학협력단 Composé radioactif pour le traitement d'un mélanome et utilisation associée

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009095872A2 (fr) * 2008-01-31 2009-08-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Analogues marqués d'halogéno-benzamides en tant que produits radiopharmaceutiques multimodaux et leurs précurseurs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2904317A1 (fr) * 2006-07-27 2008-02-01 Inst Nat Sante Rech Med Analogues d'halogenobenzamides marques a titre de radiopharmaceutiques

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009095872A2 (fr) * 2008-01-31 2009-08-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Analogues marqués d'halogéno-benzamides en tant que produits radiopharmaceutiques multimodaux et leurs précurseurs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2009129573A1 *

Also Published As

Publication number Publication date
CA2753532A1 (fr) 2009-10-29
NZ589360A (en) 2012-08-31
EP2285778A1 (fr) 2011-02-23
CN102232067A (zh) 2011-11-02
AU2009240785A1 (en) 2009-10-29
WO2009129573A1 (fr) 2009-10-29

Similar Documents

Publication Publication Date Title
HK1256310A1 (zh) N-磺酰基吡咯衍生物
IL210548A0 (en) Spiroaminodihydrothiazine derivatives
EP2376494A4 (fr) Dérivés de dihydropyrimidopirymidine
IL206276A0 (en) Pyridine derivatives
ZA201100799B (en) Imidazopyridin-2-one derivatives
ZA201201125B (en) Pyridin-4-yl derivatives
SG10201506608RA (en) 3-deazaneplanocin derivatives
ZA201100876B (en) Pyrrolopyridinylpyrimidin-2-ylamine derivatives
EP2291078A4 (fr) Dérivés d'oxazolobenzimidazole
ZA201102449B (en) Morpholinopurine derivatives
HK1148283A1 (en) Heterocyclic derivatives
EP2279532A4 (fr) Dérivés d'oxazolobenzimidazole
IL210869A0 (en) Imidazothiadiazoles derivatives
IL208336A0 (en) Pyrisazinone derivatives
ZA201100948B (en) Acylaminobenzamide derivatives
IL211290A0 (en) New 2-amidothiadiazole derivatives
IL210164A0 (en) Thiazolylpiperidine derivatives
ZA201005382B (en) Substituted heteroarylamide diazepinopyrimidone derivatives
ZA201005381B (en) Substituted heteroarylamide oxazepinopyrimidone derivatives
ZA201008052B (en) 2-phenyl-4-cyclopropyl-pyrimidine derivatives
ZA201105050B (en) Quinazolinamide derivatives
ZA201007615B (en) Aminopyridine derivatives
EP2292613A4 (fr) Dérivés de dihydroindolinone
EP2285778A4 (fr) Dérivés de nicotinamide
IL213051A0 (en) Difluorophenyldiacylhydrazide derivatives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20101122

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

A4 Supplementary search report drawn up and despatched

Effective date: 20110408

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1154582

Country of ref document: HK

17Q First examination report despatched

Effective date: 20130318

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130730

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1154582

Country of ref document: HK